News Image

Why NASDAQ:AMGN is a Top Pick for Dividend Investors.

By Mill Chart

Last update: Nov 27, 2023

Consider AMGEN INC (NASDAQ:AMGN) as a top pick for dividend investors, identified by our stock screening tool. NASDAQ:AMGN shines in terms of profitability, solvency, and liquidity, all while paying a decent dividend. Let's dive deeper into the analysis.

Evaluating Dividend: NASDAQ:AMGN

To gauge a stock's dividend quality, ChartMill utilizes a Dividend Rating ranging from 0 to 10. This comprehensive assessment considers various dividend aspects, including yield, history, growth, and sustainability. NASDAQ:AMGN has achieved a 7 out of 10:

  • AMGN's Dividend Yield is rather good when compared to the industry average which is at 42.56. AMGN pays more dividend than 98.66% of the companies in the same industry.
  • AMGN's Dividend Yield is a higher than the S&P500 average which is at 2.63.
  • On average, the dividend of AMGN grows each year by 10.76%, which is quite nice.
  • AMGN has been paying a dividend for at least 10 years, so it has a reliable track record.
  • AMGN has not decreased its dividend for at least 10 years, so it has a reliable track record of non decreasing dividend.

What does the Health looks like for NASDAQ:AMGN

Every stock is evaluated by ChartMill, receiving a Health Rating on a scale of 0 to 10. This assessment considers different health aspects, including liquidity and solvency, both in absolute terms and relative to industry peers. NASDAQ:AMGN has achieved a 5 out of 10:

  • AMGN has a better Altman-Z score (1.69) than 69.23% of its industry peers.
  • The Debt to FCF ratio of AMGN (6.45) is better than 94.48% of its industry peers.
  • A Current Ratio of 2.86 indicates that AMGN has no problem at all paying its short term obligations.
  • A Quick Ratio of 2.56 indicates that AMGN has no problem at all paying its short term obligations.

Profitability Analysis for NASDAQ:AMGN

ChartMill employs its own Profitability Rating system for stock evaluation. This score, ranging from 0 to 10, is derived from an analysis of diverse profitability metrics and margins. In the case of NASDAQ:AMGN, the assigned 8 is noteworthy for profitability:

  • AMGN has a Return On Assets of 8.36%. This is amongst the best in the industry. AMGN outperforms 96.82% of its industry peers.
  • Looking at the Return On Equity, with a value of 98.82%, AMGN belongs to the top of the industry, outperforming 99.67% of the companies in the same industry.
  • AMGN has a better Return On Invested Capital (10.97%) than 96.49% of its industry peers.
  • Measured over the past 3 years, the Average Return On Invested Capital for AMGN is above the industry average of 12.73%.
  • The 3 year average ROIC (16.82%) for AMGN is well above the current ROIC(10.97%). The reason for the recent decline needs to be investigated.
  • AMGN's Profit Margin of 28.20% is amongst the best of the industry. AMGN outperforms 97.99% of its industry peers.
  • AMGN's Profit Margin has improved in the last couple of years.
  • The Operating Margin of AMGN (33.95%) is better than 97.99% of its industry peers.
  • AMGN has a better Gross Margin (73.74%) than 83.78% of its industry peers.

Our Best Dividend screener lists more Best Dividend stocks and is updated daily.

Check the latest full fundamental report of AMGN for a complete fundamental analysis.

Disclaimer

This article should in no way be interpreted as advice in any way. The article is based on the observed metrics at the time of writing, but you should always make your own analysis and trade or invest at your own responsibility.

Back

AMGEN INC

NASDAQ:AMGN (2/23/2024, 10:48:02 AM)

291.285

+6.11 (+2.14%)

AMGN News

News Image2 hours ago - Market News VideoDow Movers: BA, AMGN
News Image4 hours ago - Investor's Business DailyWeight-Loss Drugs Have One Big Problem. These Drugmakers Are Taking It On.

Weight-loss drugs from Novo Nordisk and Eli Lilly lead to massive weight loss. But not all of that weight loss is healthy.

News Image18 hours ago - InvestorPlace3 Biotech Stocks to Turn $10,000 Into $1 Million: February 2024

With new innovation and high demand, biotech stocks could offer some of the most explosive opportunities of the year.

News Image2 days ago - Seeking AlphaRegeneron, Vertex Pharma in $100B biotech club (NASDAQ:REGN)

Regeneron (REGN) and Vertex Pharmaceuticals (VRTX) join the $100B market cap club in the biotech industry, outperforming their rivals last year. Read more here.

News Image3 days ago - Market News VideoNotable Tuesday Option Activity: AMGN, GOOG, AXSM
News Image4 days ago - AmgenAMGEN TO HOST CONFERENCE CALL ON RARE DISEASE

/PRNewswire/ -- Amgen (NASDAQ:AMGN) will host a webcasted call at 1:00 p.m. PT on Thursday, February 22, 2024 to discuss Rare Disease, its newly added fourth...

News Image6 days ago - The Motley FoolIf You Invested $20,000 in Amgen in 2014, This Is How Much You Would Have Today

Has Amgen been a market-beating stock?

News Image7 days ago - Seeking AlphaNovartis aiming to develop next-generation weight-loss drugs (NYSE:NVS)

Novartis (NVS) is jumping on the weight-loss bandwagon, aiming to develop next-generation anti-obesity drugs that could potentially address some of the drawback

News Image8 days ago - InvestorPlace7 Contrarian Biotech Stocks to Consider Amid Sector Weakness

Although the healthcare innovation space has struggled recently, these contrarian biotech stocks now offer compelling discounts.

News Image9 days ago - InvestorPlace7 Must-Buy Pharma Stocks Amid the Weight Loss Drug Revolution

Obesity drug sales boomed in 2023 and will continue in 2024. That could make these weight loss stocks even more attractive.

News Image9 days ago - The Motley Fool2 Dow Jones Dividend Stocks With Above-Average Yields to Buy Now and Hold for at Least a Decade

Investors interested in a steadily rising stream of passive income will find what they're looking for with these dividend payers.

News Image9 days ago - The Motley FoolAmgen Takes Aim at Novo Nordisk and Eli Lilly, but Is the Stock a Buy?

It faces both clinical and competitive barriers, but they might not matter.

AMGN Links
Follow us for more